Apellis Pharmaceuticals Inc Recommendation mean
What is the Recommendation mean of Apellis Pharmaceuticals Inc?
The Recommendation mean of Apellis Pharmaceuticals Inc is 1.43
What is the definition of Recommendation mean?
Recommendation mean is the mean of analysts’ ratings of the stock ranging from 1.0 (strong buy) to 5.0 (strong sell).
Mean of recommendations is an average of ratings from different analysts but it should still be used with other research and investment metrics in order to make investment decisions. It is important to understand a firm's entire scale when assimilating ratings. Additionally, analyst recommendations on stocks owned by firms employing them may be seen as potentially biased.
Financial analysts are often employed by mutual and pension funds, hedge funds, securities firms, banks, investment banks, insurance companies, and other businesses, helping these companies or their clients make investment decisions. Financial analysts employed in commercial lending perform "balance sheet analysis," examining the audited financial statements and corollary data in order to assess lending risks. In a stock brokerage house or in an investment bank, they read company financial statements and analyze commodity prices, sales, costs, expenses, and tax rates in order to determine a company's value and project future earnings. In any of these various institutions, the analyst often meets with company officials to gain a better insight into a company's prospects and to determine the company's managerial effectiveness.
Usually, financial analysts study an entire industry, assessing current trends in business practices, products, and industry competition. They must keep abreast of new regulations or policies that may affect the industry, as well as monitor the economy to determine its effect on earnings.
Recommendation mean of companies in the Health Care sector on NASDAQ compared to Apellis Pharmaceuticals Inc
What does Apellis Pharmaceuticals Inc do?
apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.
Companies with recommendation mean similar to Apellis Pharmaceuticals Inc
- LHC Inc has Recommendation mean of 1.42
- Imax Corp has Recommendation mean of 1.42
- TAL Education has Recommendation mean of 1.42
- Coherent Corp has Recommendation mean of 1.42
- Canadian Natural Resources has Recommendation mean of 1.42
- Semtech has Recommendation mean of 1.42
- Apellis Pharmaceuticals Inc has Recommendation mean of 1.43
- Addus HomeCare has Recommendation mean of 1.44
- Biolife Solutions Inc has Recommendation mean of 1.44
- Visa Inc has Recommendation mean of 1.44
- ServiceNow Inc has Recommendation mean of 1.44
- Daqo New Corp has Recommendation mean of 1.44
- ACM Research Inc has Recommendation mean of 1.44